← All trials
NCT05669625
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 26, 2022
- Primary completion
- Apr 14, 2024
- Completion date
- Sep 14, 2026
- First posted
- Jan 3, 2023
- Last posted
- Jun 18, 2023
- Enrollment
- 12440
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China National Biotec Group Co., LtdLead sponsor
- Government of ChinaCollaborator
- Government of ChinaOverall official - principal investigator
- Beijing Tiantan Bio Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.